水公司与BD的生物科学和诊断单位合并,成为生命科学和诊断方面的全球领先者。 Waters Corp. merged with BD’s biosciences and diagnostics units, creating a global leader in life sciences and diagnostics.

水公司已完成与英国开发署生物科学与诊断解决方案企业的合并,成为生命科学和诊断方面的全球领先者。 Waters Corporation has completed its merger with BD’s Biosciences & Diagnostic Solutions businesses, forming a global leader in life sciences and diagnostics. 联合公司以 " Waters " 的名义运作,现在共有四个部门,侧重于分析科学、生物科学、先进诊断和材料科学。 The combined company, operating under the Waters name, now has four divisions focusing on analytical sciences, biosciences, advanced diagnostics, and materials sciences. 这笔交易价值188亿美元,因为BD股东收到Waters股票的0.135股和40亿美元现金。 The deal, valued at $18.8 billion, saw BD shareholders receive 0.135 shares of Waters stock and $4 billion in cash. 水系指定基因组科学家Claire M. Fraser博士为董事会成员,加强了其在基因组学和分子诊断学方面的领导作用。 Waters appointed genome scientist Dr. Claire M. Fraser to its board, enhancing its leadership in genomics and molecular diagnostics. 这一一体化旨在推动药物开发、食品和环境测试以及诊断方面的创新,同时创造长期股东价值。 The integration aims to drive innovation in drug development, food and environmental testing, and diagnostics while creating long-term shareholder value.